Status:
UNKNOWN
Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR
Lead Sponsor:
Jordan Collaborating Cardiology Group
Conditions:
ATTR Amyloidosis Wild Type
Severe Aortic Stenosis
Eligibility:
All Genders
65+ years
Brief Summary
ATTR-cardiac amyloidosis (CA) is present in 4% to 16% of elderly patients with severe calcific aortic stenosis (AS). The reasons for this association are not fully known. It is hypothesized that an am...
Detailed Description
ATTR-cardiac amyloidosis (CA) is present in 4% to 16% of elderly patients with severe calcific aortic stenosis (AS). The reasons for this association are not fully known. Two hypotheses may explain th...
Eligibility Criteria
Inclusion
- Age ≥65 years
- Severe aortic stenosis
- Patient underwent TAVR procedure
- Positive pyruvate PO4 scan
Exclusion
- Diagnosis of AL amyloidosis base on free light chain assay, serum and urine immune electrophoresis.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06015997
Start Date
October 1 2023
End Date
November 1 2025
Last Update
August 29 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.